Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling.

Recent genetic knock-in and pharmacological approaches have suggested that, of class IA PI3Ks (phosphatidylinositol 3-kinases), it is the p110alpha isoform (PIK3CA) that plays the predominant role in insulin signalling. We have used isoform-selective inhibitors of class IA PI3K to dissect further the roles of individual p110 isoforms in insulin signalling. These include a p110alpha-specific inhibitor (PIK-75), a p110alpha-selective inhibitor (PI-103), a p110beta-specific inhibitor (TGX-221) and a p110delta-specific inhibitor (IC87114). Although we find that p110alpha is necessary for insulin-stimulated phosphorylation of PKB (protein kinase B) in several cell lines, we find that this is not the case in HepG2 hepatoma cells. Inhibition of p110beta or p110delta alone was also not sufficient to block insulin signalling to PKB in these cells, but, when added in combination with p110alpha inhibitors, they are able to significantly attenuate insulin signalling. Surprisingly, in J774.2 macrophage cells, insulin signalling to PKB was inhibited to a similar extent by inhibitors of p110alpha, p110beta or p110delta. These results provide evidence that p110beta and p110delta can play a role in insulin signalling and also provide the first evidence that there can be functional redundancy between p110 isoforms. Further, our results indicate that the degree of functional redundancy is linked to the relative levels of expression of each isoform in the target cells.

[1]  C. Rommel,et al.  PI3Kγ inhibition: towards an 'aspirin of the 21st century'? , 2006, Nature Reviews Drug Discovery.

[2]  M. Waterfield,et al.  Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. , 2006, Bioorganic & medicinal chemistry.

[3]  C. Rommel,et al.  Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. , 2006, Journal of medicinal chemistry.

[4]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[5]  K. Okkenhaug,et al.  Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation , 2006, Nature.

[6]  B. Vanhaesebroeck,et al.  Oncogenic transformation induced by the p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[7]  P. Ladenson,et al.  Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. , 2005, The Journal of clinical endocrinology and metabolism.

[8]  S. Schwartz,et al.  The prevalence of PIK3CA mutations in gastric and colon cancer. , 2005, European journal of cancer.

[9]  A. Robertson,et al.  PI 3-kinase p110β: a new target for antithrombotic therapy , 2005, Nature Medicine.

[10]  A. Lash,et al.  Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers , 2005, Clinical Cancer Research.

[11]  J. Engelman,et al.  Phosphoinositide 3-Kinase Catalytic Subunit Deletion and Regulatory Subunit Deletion Have Opposite Effects on Insulin Sensitivity in Mice , 2005, Molecular and Cellular Biology.

[12]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[13]  Hiroyuki Konishi,et al.  The PIK3CA gene is mutated with high frequency in human breast cancers , 2004, Cancer biology & therapy.

[14]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[15]  J. A. Radding,et al.  Cloning, expression, purification, and characterization of the human Class Ia phosphoinositide 3-kinase isoforms. , 2004, Protein expression and purification.

[16]  J. Klein,et al.  Positive and Negative Roles of p85α and p85β Regulatory Subunits of Phosphoinositide 3-Kinase in Insulin Signaling* , 2003, Journal of Biological Chemistry.

[17]  アボット，ベリンダ,et al.  Inhibition of phosphoinositide 3-kinase β , 2003 .

[18]  P. Bamborough,et al.  Condensed heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of, inter alia, rheumatoid arthritis. , 2003 .

[19]  D. Staunton,et al.  Essential Role of Phosphoinositide 3-Kinase δ in Neutrophil Directional Movement , 2003, The Journal of Immunology.

[20]  K. Okkenhaug,et al.  Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice , 2002, Science.

[21]  R. Nussbaum,et al.  Early embryonic lethality in mice deficient in the p110β catalytic subunit of PI 3-kinase , 2002, Mammalian Genome.

[22]  J. Treiberg,et al.  Inhibitors phosphatidylinositol 3-kinase delta human , 2001 .

[23]  P. Shepherd,et al.  Comparison of the kinetic properties of the lipid- and protein-kinase activities of the p110α and p110β catalytic subunits of class-Ia phosphoinositide 3-kinases , 2000 .

[24]  Y. Yazaki,et al.  p110β Is Up-regulated during Differentiation of 3T3-L1 Cells and Contributes to the Highly Insulin-responsive Glucose Transport Activity* , 2000, The Journal of Biological Chemistry.

[25]  C. Heldin,et al.  The PI 3-kinase isoforms p110(alpha) and p110(beta) have differential roles in PDGF- and insulin-mediated signaling. , 2000, Journal of cell science.

[26]  M. Waterfield,et al.  Signaling by distinct classes of phosphoinositide 3-kinases. , 1999, Experimental cell research.

[27]  R. Nussbaum,et al.  Proliferative Defect and Embryonic Lethality in Mice Homozygous for a Deletion in the p110α Subunit of Phosphoinositide 3-Kinase* , 1999, The Journal of Biological Chemistry.

[28]  Y. Matsuzawa,et al.  Increased insulin sensitivity and hypoglycaemia in mice lacking the p85α subunit of phosphoinositide 3–kinase , 1999, Nature Genetics.

[29]  L. Pirola,et al.  Structure and function of phosphoinositide 3-kinases. , 1998, Biochimica et biophysica acta.

[30]  J. Downward,et al.  A Function for Phosphatidylinositol 3-Kinase β (p85α-p110β) in Fibroblasts during Mitogenesis: Requirement for Insulin- and Lysophosphatidic Acid-Mediated Signal Transduction , 1998, Molecular and Cellular Biology.

[31]  A. Klip,et al.  Opposite effects of insulin on focal adhesion proteins in 3T3-L1 adipocytes and in cells overexpressing the insulin receptor. , 1998, Molecular biology of the cell.

[32]  K. Siddle,et al.  Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. , 1998, The Biochemical journal.

[33]  S. Hoshino,et al.  Heterodimeric Phosphoinositide 3-Kinase Consisting of p85 and p110β Is Synergistically Activated by the βγ Subunits of G Proteins and Phosphotyrosyl Peptide* , 1997, The Journal of Biological Chemistry.

[34]  K. Siddle,et al.  Differential Regulation of Phosphoinositide 3-Kinase Adapter Subunit Variants by Insulin in Human Skeletal Muscle* , 1997, The Journal of Biological Chemistry.

[35]  M. Zvelebil,et al.  p110δ, a novel phosphoinositide 3-kinase in leukocytes , 1997 .

[36]  F. Schmook,et al.  The pharmaceutical compounds , 1997 .

[37]  K. Siddle,et al.  Compartment-specific regulation of phosphoinositide 3-kinase by platelet-derived growth factor and insulin in 3T3-L1 adipocytes. , 1996, The Biochemical journal.

[38]  N. Konstantopoulos,et al.  Insulin and insulin-like growth factor-1 stimulate dephosphorylation of paxillin in parallel with focal adhesion kinase. , 1996, The Biochemical journal.

[39]  K Y Hui,et al.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.

[40]  A. Arcaro,et al.  Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. , 1993, The Biochemical journal.

[41]  G. Firestone,et al.  Insulin receptor monoclonal antibodies that mimic insulin action without activating tyrosine kinase. , 1989, The Journal of biological chemistry.

[42]  久保 裕嗣.  Specific role for p85/p110β in GTP-binding-protein-mediated activation of Akt , 2006 .

[43]  P. Shepherd.  Mechanisms regulating phosphoinositide 3-kinase signalling in insulin-sensitive tissues. , 2005, Acta physiologica Scandinavica.

[44]  M. Waterfield,et al.  Synthesis and function of 3-phosphorylated inositol lipids. , 2001, Annual review of biochemistry.

[45]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.